Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies (Q34407994)

2 August 2017

1 reference

title

Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies (English)

1 reference

2 August 2017

1 reference

1 reference

Ruprecht RM

1

1 reference

2 August 2017

Hofmann-Lehmann R

2

1 reference

2 August 2017

Smith-Franklin BA

3

1 reference

2 August 2017

Rasmussen RA

4

1 reference

2 August 2017

Liska V

5

1 reference

2 August 2017

Vlasak J

6

1 reference

2 August 2017

Xu W

7

1 reference

2 August 2017

Baba TW

8

1 reference

2 August 2017

Chenine AL

9

1 reference

2 August 2017

Cavacini LA

10

1 reference

2 August 2017

Posner MR

11

1 reference

2 August 2017

Katinger H

12

1 reference

2 August 2017

Stiegler G

13

1 reference

2 August 2017

Bernacky BJ

14

1 reference

2 August 2017

Rizvi TA

15

1 reference

2 August 2017

Schmidt R

16

1 reference

2 August 2017

Hill LR

17

1 reference

2 August 2017

Keeling ME

18

1 reference

2 August 2017

Montefiori DC

19

1 reference

2 August 2017

McClure HM

20

1 reference

2 August 2017

1 August 2001

1 reference

Transfusion Clinique et Biologique

2 August 2017

1 reference

2 August 2017

8

1 reference

2 August 2017

350-358

1 reference

2 August 2017

4

1 reference

Mucosal infection of neonatal rhesus monkeys with cell-free SIV

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

Phase I Study of a Human Monoclonal Antibody Directed against the CD4-Binding Site of HIV Type 1 Glycoprotein 120

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

Characterization of primary isolate-like variants of simian-human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

High risk of HIV-1 infection for first-born twins. The International Registry of HIV-exposed Twins

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

The envelope glycoprotein ectodomains determine the efficiency of CD4+ T lymphocyte depletion in simian-human immunodeficiency virus-infected macaques

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

Utility of SHIV for testing HIV-1 vaccine candidates in macaques.

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

Role of complement and Fc receptors in the pathogenesis of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

Fetal or neonatal infection with attenuated simian immunodeficiency virus results in protective immunity against oral challenge with pathogenic SIVmac251.

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

Viral burden and disease progression in rhesus monkeys infected with chimeric simian-human immunodeficiency viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

Reducing the risk of maternal-infant transmission of HIV by attacking the virus

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

Oral transmission of primate lentiviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

The antigenic structure of the HIV gp120 envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS1246-7820%2801%2900187-2

7 January 2021

10.1016/S1246-7820(01)00187-2

Identifiers

DOI

1 reference

2 August 2017

1 reference